At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 254 enrolled
Drug / intervention
CF101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating CF101 for Rheumatoid Arthritis. Completed, enrolled 254 participants across 35 sites in 7 countries.
Detailed Summary
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Israel, Poland, Romania, Serbia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2006
Enrollment StartJun 2006
Primary CompletionApr 2007
TodayJul 2026
First PostedJan 24, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.4 years ago
Interventions
CF101drug